<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02245867</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM5108</org_study_id>
    <secondary_id>FDA Grant R01FD005110</secondary_id>
    <nct_id>NCT02245867</nct_id>
  </id_info>
  <brief_title>Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis</brief_title>
  <official_title>Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Eisenberger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the tolerance, safety, pharmakinetics, and possible&#xD;
      clinical benefit of the good manufacturing practice (GMP)-grade amyloid fibril-reactive&#xD;
      chimeric (Ch) IgG1 mAb 11-1F4 in patients with amyloid light-chain (AL) amyloidosis.&#xD;
&#xD;
      The phase 1a part will involve at least 3 patients and a maximum of 18 patients. The first&#xD;
      patient will receive the starting dose of the antibody and, if tolerated, the following&#xD;
      patients will each receive (if tolerated) progressively higher doses of the antibody.&#xD;
      Patients in part 1a of the trial will receive only one infusion of the drug. Patients treated&#xD;
      in the phase 1a part receive lower dosage which might not be effective.&#xD;
&#xD;
      Once the maximal tolerated dosage is established during the phase 1a part, the investigators&#xD;
      will accrue patients to the phase 1b part of the trial. Patients will receive 4 infusions,&#xD;
      once each week for 4 weeks. Patients who were treated in the part 1a of the trial and showed&#xD;
      no toxicity can be also treated in the part 1b of the trial. The first patient will receive&#xD;
      the starting dose of the antibody and, if tolerated, the following patients will each receive&#xD;
      (if tolerated) progressively higher doses of the antibody. When the investigators reach the&#xD;
      maximum tolerated dose without toxicity, the investigators e will enroll another 4 patients&#xD;
      to receive the same dose. If there are no toxicities, another 4 patients will be treated at&#xD;
      the next dose level, and so forth. Patients treated in Phase 1b may receive lower dosages&#xD;
      which might not be effective. The goal of Phase 1b is to establish the tolerance and possible&#xD;
      beneficial effects of 11-1F4. If successful, treatment with this antibody would represent a&#xD;
      novel approach in the care of individuals with AL amyloidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presently, treatment of patients with amyloid light chain (AL) amyloidosis is limited to&#xD;
      reducing production of the amyloid-forming light-chain protein by giving conventional or&#xD;
      high-dose (with stem cell transplant) anti-plasma cell chemotherapy, as used for patients&#xD;
      with multiple myeloma. Although this approach has extended survival, the prognosis remains&#xD;
      poor due to the persistence or progression of the amyloid deposits in vital organs, such as&#xD;
      the heart or kidney. A different treatment strategy would be to attempt to reduce and/or&#xD;
      eliminate these deposits. This study evaluates this by administering an anti-amyloid&#xD;
      monoclonal antibody, 11-1F4. This compound has been shown to reduce/destroy this material in&#xD;
      an experimental animal model of amyloidosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2014</start_date>
  <completion_date type="Actual">July 23, 2017</completion_date>
  <primary_completion_date type="Actual">July 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Ch mAb 11-1F4</measure>
    <time_frame>2 years approximately</time_frame>
    <description>The MTD of a single application of Ch mAb 11-1F4 is defined as the highest safely-tolerated dose (mg/m2) where 0 patients experiences Dose Limiting Toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with positive amyloid-related organ response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Amyloid-related organ response will be evaluated on the basis of the accepted criteria per consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, in patients who completed phase 1b.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated mean area under the curve (AUC) for Ch mAb 11-1F4</measure>
    <time_frame>Phase 1a: 1, 2, 24 hours post start of infusion; then post-infusion week 1, 2, 3, 4, 8. Phase 1b: pretreatment, 1, 2, 24 hours post start of infusion; then post-infusion week 5, 8, 12.</time_frame>
    <description>This is designed to determine the pharmacokinetics of Ch mAb 11-1F4 when given as a single intravenous (i.v.) infusion (phase 1a) or as a series of four weekly intravenous infusions (phase 1b).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>2 years approximately</time_frame>
    <description>This to obtain additional safety data of Ch mAb 11-1F4 when given as a single intravenous infusion (phase 1a) or as a series of four weekly intravenous infusions (phase 1b) by obtaining adverse event information for all subjects during active follow-up visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Phase Ia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:&#xD;
A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase Ib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:&#xD;
Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4</intervention_name>
    <description>The antibody binds to the pathologic material and initiates a neutrophil/macrophage response</description>
    <arm_group_label>Phase Ia</arm_group_label>
    <arm_group_label>Phase Ib</arm_group_label>
    <other_name>Ch mAb 11-1F4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a confirmed diagnosis of AL amyloidosis based on accepted clinical&#xD;
             and laboratory criteria.&#xD;
&#xD;
          -  Patients are greater than 21 years old.&#xD;
&#xD;
               -  Female patients are not of child bearing potential or if they are of child&#xD;
                  bearing potential, they must not be pregnant or breast-feeding.&#xD;
&#xD;
               -  Patients have a life expectancy greater than 3 months.&#xD;
&#xD;
               -  Patients have an Eastern Cooperative Oncology Group (ECOG)-specified performance&#xD;
                  status of less than or equal to 3.&#xD;
&#xD;
          -  Patients to be included are those with measurable, localized amyloid deposits (larynx,&#xD;
             subcutaneous tissue, muscle, lung, lymph nodes) or clinically evident systemic disease&#xD;
             (liver, kidney, heart, etc).&#xD;
&#xD;
          -  Only patients with prior systemic therapy with relapsed/refractory disease are&#xD;
             eligible, unless they have declined or are not eligible for high-dose melphalan and&#xD;
             autologous hematopoietic stem cell transplant (HSCT) or any other standard therapy&#xD;
             that has been known to be life-prolonging or life-saving.&#xD;
&#xD;
          -  Patients have adequate organ function.&#xD;
&#xD;
          -  Patients with cancer are eligible provided they meet specific criteria.&#xD;
&#xD;
          -  Patients must provide signed, written, informed consent and be willing and able to&#xD;
             comply with eligibility requirements, scheduled, visits, and follow-up studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-AL amyloidosis.&#xD;
&#xD;
          -  Renal failure (on dialysis).&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding.&#xD;
&#xD;
          -  ECOG Performance Status greater than 3.&#xD;
&#xD;
          -  Seriously limited cardiac, renal, or hepatic function.&#xD;
&#xD;
          -  Uncontrolled infection or significant co-morbidity (e.g., uncontrolled diabetes,&#xD;
             severe diarrhea).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Eisenberger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Solomon, A. and Weiss, D.T. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid: Inter. J. Exper. Clin. Invest. 2: 269-279, 1995.</citation>
  </reference>
  <reference>
    <citation>Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995 Jan;32(1):45-59. No abstract available.</citation>
    <PMID>7878478</PMID>
  </reference>
  <reference>
    <citation>Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144. No abstract available.</citation>
    <PMID>12904524</PMID>
  </reference>
  <reference>
    <citation>Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. doi: 10.1056/NEJM199704243361702.</citation>
    <PMID>9110907</PMID>
  </reference>
  <reference>
    <citation>Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C, Ascari E, Merlini G. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol. 2001 Jun;113(4):1044-6. doi: 10.1046/j.1365-2141.2001.02859.x.</citation>
    <PMID>11442500</PMID>
  </reference>
  <reference>
    <citation>Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002 Jun 15;99(12):4276-82. doi: 10.1182/blood.v99.12.4276.</citation>
    <PMID>12036853</PMID>
  </reference>
  <reference>
    <citation>Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004 Jan 20;140(2):85-93. doi: 10.7326/0003-4819-140-2-200401200-00008.</citation>
    <PMID>14734330</PMID>
  </reference>
  <reference>
    <citation>Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, Bello C, Hoover E, Riedel E, Giralt S, Comenzo RL. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013 Apr;27(4):823-8. doi: 10.1038/leu.2012.274. Epub 2012 Sep 27.</citation>
    <PMID>23014566</PMID>
  </reference>
  <reference>
    <citation>O'Nuallain B, Allen A, Kennel SJ, Weiss DT, Solomon A, Wall JS. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry. 2007 Feb 6;46(5):1240-7. doi: 10.1021/bi0616605.</citation>
    <PMID>17260953</PMID>
  </reference>
  <reference>
    <citation>O'Nuallain B, Allen A, Ataman D, Weiss DT, Solomon A, Wall JS. Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry. 2007 Nov 13;46(45):13049-58. doi: 10.1021/bi701255m. Epub 2007 Oct 18.</citation>
    <PMID>17944486</PMID>
  </reference>
  <reference>
    <citation>Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000 Oct;157(4):1239-46. doi: 10.1016/S0002-9440(10)64639-1.</citation>
    <PMID>11021828</PMID>
  </reference>
  <reference>
    <citation>Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003 Dec;18(6):853-60. doi: 10.1089/108497803322702824.</citation>
    <PMID>14969598</PMID>
  </reference>
  <reference>
    <citation>Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, Moll T, Saito T, Verbeek JS, Botto M, Walport MJ, Carroll M, Izui S. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med. 2002 Mar 18;195(6):665-72. doi: 10.1084/jem.20012024.</citation>
    <PMID>11901193</PMID>
  </reference>
  <reference>
    <citation>Wall J, Murphy CL, Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 1999;309:204-17. doi: 10.1016/s0076-6879(99)09016-3.</citation>
    <PMID>10507026</PMID>
  </reference>
  <reference>
    <citation>Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3831S-8S.</citation>
    <PMID>14506180</PMID>
  </reference>
  <reference>
    <citation>Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug;79(4):319-28. doi: 10.1002/ajh.20381.</citation>
    <PMID>16044444</PMID>
  </reference>
  <reference>
    <citation>Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, Solomon A. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol. 2008 Nov;130(5):702-11. doi: 10.1309/AJCPNS6K1CYJPDBA.</citation>
    <PMID>18854262</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 15, 2014</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2014</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Andrew Eisenberger</investigator_full_name>
    <investigator_title>Associate Professor of Medicine at the Columbia University Medical Center, Dept of Med Hematology &amp; Onc</investigator_title>
  </responsible_party>
  <keyword>Amyloidosis</keyword>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02245867
org study id: AAAM5108
secondary id: FDA Grant R01FD005110
nct id: NCT02245867
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to examine the tolerance, safety, pharmakinetics, and possible
      clinical benefit of the good manufacturing practice (GMP)-grade amyloid fibril-reactive
      chimeric (Ch) IgG1 mAb 11-1F4 in patients with amyloid light-chain (AL) amyloidosis.

      The phase 1a part will involve at least 3 patients and a maximum of 18 patients. The first
      patient will receive the starting dose of the antibody and, if tolerated, the following
      patients will each receive (if tolerated) progressively higher doses of the antibody.
      Patients in part 1a of the trial will receive only one infusion of the drug. Patients treated
      in the phase 1a part receive lower dosage which might not be effective.

      Once the maximal tolerated dosage is established during the phase 1a part, the investigators
      will accrue patients to the phase 1b part of the trial. Patients will receive 4 infusions,
      once each week for 4 weeks. Patients who were treated in the part 1a of the trial and showed
      no toxicity can be also treated in the part 1b of the trial. The first patient will receive
      the starting dose of the antibody and, if tolerated, the following patients will each receive
      (if tolerated) progressively higher doses of the antibody. When the investigators reach the
      maximum tolerated dose without toxicity, the investigators e will enroll another 4 patients
      to receive the same dose. If there are no toxicities, another 4 patients will be treated at
      the next dose level, and so forth. Patients treated in Phase 1b may receive lower dosages
      which might not be effective. The goal of Phase 1b is to establish the tolerance and possible
      beneficial effects of 11-1F4. If successful, treatment with this antibody would represent a
      novel approach in the care of individuals with AL amyloidosis.
Presently, treatment of patients with amyloid light chain (AL) amyloidosis is limited to
      reducing production of the amyloid-forming light-chain protein by giving conventional or
      high-dose (with stem cell transplant) anti-plasma cell chemotherapy, as used for patients
      with multiple myeloma. Although this approach has extended survival, the prognosis remains
      poor due to the persistence or progression of the amyloid deposits in vital organs, such as
      the heart or kidney. A different treatment strategy would be to attempt to reduce and/or
      eliminate these deposits. This study evaluates this by administering an anti-amyloid
      monoclonal antibody, 11-1F4. This compound has been shown to reduce/destroy this material in
      an experimental animal model of amyloidosis.
allocation: Non-Randomized
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Maximum Tolerated Dose (MTD) of Ch mAb 11-1F4
time frame: 2 years approximately
description: The MTD of a single application of Ch mAb 11-1F4 is defined as the highest safely-tolerated dose (mg/m2) where 0 patients experiences Dose Limiting Toxicity.
measure: Number of subjects with positive amyloid-related organ response
time frame: 12 weeks
description: Amyloid-related organ response will be evaluated on the basis of the accepted criteria per consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis, in patients who completed phase 1b.
measure: Estimated mean area under the curve (AUC) for Ch mAb 11-1F4
time frame: Phase 1a: 1, 2, 24 hours post start of infusion; then post-infusion week 1, 2, 3, 4, 8. Phase 1b: pretreatment, 1, 2, 24 hours post start of infusion; then post-infusion week 5, 8, 12.
description: This is designed to determine the pharmacokinetics of Ch mAb 11-1F4 when given as a single intravenous (i.v.) infusion (phase 1a) or as a series of four weekly intravenous infusions (phase 1b).
measure: Number of participants with adverse events
time frame: 2 years approximately
description: This to obtain additional safety data of Ch mAb 11-1F4 when given as a single intravenous infusion (phase 1a) or as a series of four weekly intravenous infusions (phase 1b) by obtaining adverse event information for all subjects during active follow-up visits.
arm group label: Phase Ia
arm group type: Experimental
description: Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:
A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks.
arm group label: Phase Ib
arm group type: Experimental
description: Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:
Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12.
intervention type: Drug
intervention name: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
description: The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
arm group label: Phase Ia
arm group label: Phase Ib
other name: Ch mAb 11-1F4
criteria: 
gender: All
minimum age: 21 Years
maximum age: N/A
healthy volunteers: No
last name: Andrew Eisenberger, MD
role: Principal Investigator
affiliation: CUMC
facility: 
country: United States
citation: Solomon, A. and Weiss, D.T. Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). Amyloid: Inter. J. Exper. Clin. Invest. 2: 269-279, 1995.
citation: Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995 Jan;32(1):45-59. No abstract available.
PMID: 7878478
citation: Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003 Aug 7;349(6):583-96. doi: 10.1056/NEJMra023144. No abstract available.
PMID: 12904524
citation: Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202-7. doi: 10.1056/NEJM199704243361702.
PMID: 9110907
citation: Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C, Ascari E, Merlini G. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol. 2001 Jun;113(4):1044-6. doi: 10.1046/j.1365-2141.2001.02859.x.
PMID: 11442500
citation: Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002 Jun 15;99(12):4276-82. doi: 10.1182/blood.v99.12.4276.
PMID: 12036853
citation: Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004 Jan 20;140(2):85-93. doi: 10.7326/0003-4819-140-2-200401200-00008.
PMID: 14734330
citation: Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, Bello C, Hoover E, Riedel E, Giralt S, Comenzo RL. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013 Apr;27(4):823-8. doi: 10.1038/leu.2012.274. Epub 2012 Sep 27.
PMID: 23014566
citation: O'Nuallain B, Allen A, Kennel SJ, Weiss DT, Solomon A, Wall JS. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry. 2007 Feb 6;46(5):1240-7. doi: 10.1021/bi0616605.
PMID: 17260953
citation: O'Nuallain B, Allen A, Ataman D, Weiss DT, Solomon A, Wall JS. Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry. 2007 Nov 13;46(45):13049-58. doi: 10.1021/bi701255m. Epub 2007 Oct 18.
PMID: 17944486
citation: Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol. 2000 Oct;157(4):1239-46. doi: 10.1016/S0002-9440(10)64639-1.
PMID: 11021828
citation: Solomon A, Weiss DT, Wall JS. Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm. 2003 Dec;18(6):853-60. doi: 10.1089/108497803322702824.
PMID: 14969598
citation: Azeredo da Silveira S, Kikuchi S, Fossati-Jimack L, Moll T, Saito T, Verbeek JS, Botto M, Walport MJ, Carroll M, Izui S. Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody. J Exp Med. 2002 Mar 18;195(6):665-72. doi: 10.1084/jem.20012024.
PMID: 11901193
citation: Wall J, Murphy CL, Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 1999;309:204-17. doi: 10.1016/s0076-6879(99)09016-3.
PMID: 10507026
citation: Solomon A, Weiss DT, Wall JS. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3831S-8S.
PMID: 14506180
citation: Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug;79(4):319-28. doi: 10.1002/ajh.20381.
PMID: 16044444
citation: Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, Solomon A. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol. 2008 Nov;130(5):702-11. doi: 10.1309/AJCPNS6K1CYJPDBA.
PMID: 18854262
responsible party type: Sponsor-Investigator
investigator affiliation: Columbia University
investigator full name: Andrew Eisenberger
investigator title: Associate Professor of Medicine at the Columbia University Medical Center, Dept of Med Hematology & Onc
mesh term: Immunoglobulin Light-chain Amyloidosis
mesh term: Amyloidosis
mesh term: Antibodies
mesh term: Antibodies, Monoclonal
sharing ipd: Undecided